Retrospective data show that relapse-free survival outcomes were worse for patients with MDS/MPN compared with those who had other types of MDS.
Fernando Duarte, MD, PhD
Advertisement
Articles by Fernando Duarte, MD, PhD
Researchers and clinicians share key updates in leukemia, lymphoma, and myelodysplastic syndrome that they presented at the 2026 Tandem Meetings.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC
3
Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC
4
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
5